Tiziana enrols first patient in Phase IIa trial of milciclib to treat HCC

UK-based biotechnology firm Tiziana Life Sciences has started patient enrolment in a Phase IIa clinical trial of milciclib for the treatment of hepatocellular carcinoma (HCC) patients.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news